Shingrix Clinical Trials
7 recruitingBiologic
Phase 13Phase 23Phase 42Phase 31
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
Herpes Zoster
National Institute of Allergy and Infectious Diseases (NIAID)225 enrolled1 locationNCT05580458
Recruiting
Phase 3
Shingrix in Renal Transplant Recipients
Kidney FailureKidney TransplantationKidney Failure, Chronic+2 more
University of Colorado, Denver132 enrolled4 locationsNCT04128189
Recruiting
Phase 4
Vaccine Responses in Patients With B Cell Malignancies
Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)500 enrolled1 locationNCT05170399
Recruiting
Phase 1Phase 2
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
vaccine preventable diseasesHerpes ZosterShingles
Dynavax Technologies Corporation764 enrolled13 locationsNCT06569823
Recruiting
Phase 4
VZV in the Enteric Nervous System: Pathogenesis and Consequences
achalasia
Vanderbilt University Medical Center40 enrolled1 locationNCT05550194
Recruiting
Phase 1
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
vaccine preventable diseasesHerpes Zoster
CHA Vaccine Institute Co., Ltd.32 enrolled2 locationsNCT06137755
Recruiting
Phase 2
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Shingles
Loyola University100 enrolled1 locationNCT05554068